1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. South and Central America Late Stage Chronic Kidney Disease Drugs Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. South and Central America Late Stage Chronic Kidney Disease Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. South and Central America Late Stage Chronic Kidney Disease Drugs Market Regional Analysis
6.2 South and Central America Late Stage Chronic Kidney Disease Drugs Market Revenue 2017-2027 (US$ Million)
6.3 South and Central America Late Stage Chronic Kidney Disease Drugs Market Forecast Analysis
7. South and Central America Late Stage Chronic Kidney Disease Drugs Market Analysis – by Product Type
7.1 Calcimimetics
- 7.1.1 Overview
- 7.1.2 Calcimimetics: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Vitamin D
- 7.2.1 Overview
- 7.2.2 Vitamin D: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.3 Sterols
- 7.3.1 Overview
- 7.3.2 Sterols: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.4 Potassium Binders
- 7.4.1 Overview
- 7.4.2 Potassium Binders: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.5 Calcium-Based Phosphate Binders
- 7.5.1 Overview
- 7.5.2 Calcium-Based Phosphate Binders: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. South and Central America Late Stage Chronic Kidney Disease Drugs Market Analysis – by Indication
8.1 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
- 8.1.1 Overview
- 8.1.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
- 8.2.1 Overview
- 8.2.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.3 Late Stage Chronic Kidney Disease Induced Hyperkalaemia
- 8.3.1 Overview
- 8.3.2 Late Stage Chronic Kidney Disease Induced Hyperkalaemia: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. South and Central America Late Stage Chronic Kidney Disease Drugs Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Online Pharmacies
- 9.2.1 Overview
- 9.2.2 Online Pharmacies: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Retail Pharmacies
- 9.3.1 Overview
- 9.3.2 Retail Pharmacies: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. South and Central America Late Stage Chronic Kidney Disease Drugs Market – South and Central America Analysis
10.1 Overview
10.2 South and Central America
- 10.2.1 South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.2.1.1 South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 Brazil:
South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.1.1 Brazil: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.2.1.1.2 Brazil: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.2.1.1.3 Brazil: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.2.1.2 Argentina:
South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.2.1 Argentina: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.2.1.2.2 Argentina: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.2.1.2.3 Argentina: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.2.1.3 Rest of South and Central America :
South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.3.1 Rest of South and Central America : South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.2.1.3.2 Rest of South and Central America : South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.2.1.3.3 Rest of South and Central America : South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 AbbVie Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Amgen
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 AstraZeneca
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Sanofi
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Kyowa Kirin Co., Ltd
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Bayer AG
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Vifor Pharma Management Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Akebia Therapeutics, Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations